GSK 과거 순이익 실적

과거 기준 점검 5/6

GSK은 연평균 0.3%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 12.2% 증가했습니다. 매출은 연평균 4.4%의 비율로 증가했습니다. GSK의 자기자본이익률은 39.4%이고 순이익률은 17.5%입니다.

핵심 정보

0.25%

순이익 성장률

-0.23%

주당순이익(EPS) 성장률

Pharmaceuticals 산업 성장률	5.95%
매출 성장률	4.39%
자기자본이익률	39.41%
순이익률	17.50%
최근 순이익 업데이트	31 Dec 2025

최근 과거 실적 업데이트

Recent updates

매출 및 비용 세부 내역

GSK가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

OTCPK:GLAX.F 매출, 비용 및 순이익 (GBP Millions)
날짜	매출	순이익	일반관리비	연구개발비
31 Dec 25	32,667	5,716	9,013	6,654
30 Sep 25	32,166	5,494	8,968	6,352
30 Jun 25	31,631	3,423	10,573	6,218
31 Mar 25	31,529	3,153	10,831	6,102
31 Dec 24	31,376	2,575	10,847	6,078
30 Sep 24	31,311	2,511	10,821	6,041
30 Jun 24	31,446	4,033	9,266	6,048
31 Mar 24	30,740	4,484	9,143	5,955
31 Dec 23	30,328	4,928	9,156	5,823
30 Sep 23	29,652	6,078	8,965	5,580
30 Jun 23	29,334	5,373	8,767	5,436
31 Mar 23	29,085	4,455	8,460	5,282
31 Dec 22	29,324	4,461	8,179	5,153
30 Sep 22	29,024	3,387	7,803	4,905
30 Jun 22	27,822	3,505	7,429	4,741
31 Mar 22	26,731	4,013	7,104	4,691
31 Dec 21	24,696	3,316	6,784	4,627
30 Sep 21	26,359	3,567	7,436	4,640
30 Jun 21	28,378	3,934	8,285	4,566
31 Mar 21	30,164	4,983	9,176	4,622
31 Dec 20	24,354	4,873	7,041	4,397
30 Sep 20	34,259	6,371	10,719	4,537
30 Jun 20	34,998	6,679	11,085	4,648
31 Mar 20	35,183	5,380	10,993	4,519
31 Dec 19	33,754	4,645	10,962	4,405
30 Sep 19	33,052	4,561	10,103	4,266
30 Jun 19	31,759	4,427	9,575	4,065
31 Mar 19	31,260	3,904	9,488	3,887
31 Dec 18	30,821	3,623	9,500	3,799
30 Sep 18	30,263	1,862	9,234	3,755
30 Jun 18	30,014	1,656	9,185	3,696
31 Mar 18	30,024	1,035	9,143	3,890
31 Dec 17	30,186	1,532	9,424	3,925
30 Sep 17	30,133	2,335	9,303	3,886
30 Jun 17	29,832	1,931	9,260	3,863
31 Mar 17	29,044	1,676	9,017	3,604
31 Dec 16	27,889	912	8,852	3,550
30 Sep 16	26,589	301	8,553	3,370
30 Jun 16	25,174	31	8,025	3,226
31 Mar 16	24,530	615	8,097	3,163
31 Dec 15	23,923	8,422	9,232	3,560
30 Sep 15	23,823	9,809	7,810	3,218
30 Jun 15	23,342	9,672	7,425	3,227

양질의 수익: GLAX.F는 고품질 수익을 보유하고 있습니다.

이익 마진 증가: GLAX.F의 현재 순 이익률 (17.5%)은 지난해 (8.2%)보다 높습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: GLAX.F의 수익은 지난 5년 동안 연평균 0.3% 증가했습니다.

성장 가속화: 지난 1년간 GLAX.F 의 수익 증가율(122%)은 연간 평균(0.3%)을 초과합니다.

수익 대 산업: GLAX.F의 지난 1년 수익 증가율(122%)은 Pharmaceuticals 업계의 6.6%를 상회했습니다.

자기자본이익률

높은 ROE: GLAX.F의 자본 수익률(39.41%)은 높음이지만 높은 부채 수준으로 인해 왜곡되어 있습니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/04/10 13:25
종가	2026/04/10 00:00
수익	2025/12/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

GSK plc는 46명의 분석가가 다루고 있습니다. 이 중 19명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research
James Gordon	Barclays

GSK 과거 순이익 실적

과거 기준 점검 5/6

핵심 정보

최근 과거 실적 업데이트

GSK plc to Report Q4, 2025 Results on Feb 04, 2026

GSK plc to Report Q3, 2025 Results on Oct 29, 2025

GSK plc to Report Q1, 2025 Results on Apr 30, 2025

GSK plc to Report Q4, 2024 Results on Feb 05, 2025

Recent updates

GSK plc Announces Exdensur Approval for CRSwNP in China

Samsung Biologics America, Inc completed the acquisition of Human Genome Sciences Inc. from GSK plc (LSE:GSK).

Bepirovirsen Accepted for Regulatory Review in China as A Potential First-In-Class Functional Cure for Chronic Hepatitis B

GSK PLC Bepirovirsen Accepted For Review By The European Medicines Agency As A Potential First-In-Class Treatment For Chronic Hepatitis B

GSK plc, Annual General Meeting, May 06, 2026

US Food and Drug Administration Approves GSK plc's Lynavoy(linerixibat)

GSK plc Announces Expansion of AREXVY Approval to Adults Aged 18 to 49 Years for RSV Prevention

Angeion Group Announces Proposed Settlement in DeCostanzo v. GlaxoSmithKline

GSK plc Appoints Elizabeth McKee Anderson as Member of the Corporate Responsibility Committee, Effective March 9, 2026

GSK plc (LSE:GSK) completed the acquisition of 93.4% stake in RAPT Therapeutics, Inc. (NasdaqGM:RAPT) for $1.7 billion.

GSK plc Announces That Japan's Ministry of Health, Labour and Welfare Accepts for Review A New Drug Application for Bepirovirsen

GSK plc (LSE:GSK) entered an agreement to acquire 35Pharma Inc for CAD 950 million.

GSK plc Announces New Effectiveness Data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) At RSVVW'26

GSK plc's RSV Vaccine Accepts for Review by China's Center for Drug Evaluation for the Prevention of Lower Respiratory Syncytial Virus Disease

GSK plc Announces Nucala (Mepolizumab) Approval by European Commission for Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Gsk Plc's Rsv Vaccine Receives European Approval for Expanded Use in All Adults 18 Years and Older

GSK plc (LSE:GSK) entered a definitive agreement to acquire RAPT Therapeutics, Inc. (NasdaqGM:RAPT) for $1.7 billion.

GSK plc to Report Q4, 2025 Results on Feb 04, 2026

GSK plc Appoints Luke Victor Miels as Director, Effective January 1, 2026

GSK plc Announces Positive Topline Results from B-Well 1 and B-Well 2 Phase 3 Studies for Bepirovirsen

GSK plc Announces the Approval of Exdensur ( Depemokimab) by Japan's Ministry of Health, Labour and Welfare

GSK plc Announces China's National Medical Products Administration Approval of Nucala (Mepolizumab) as Add-On Maintenance Treatment of Adult Patients with Inadequately Controlled COPD

Samsung Biologics America, Inc. entered into a definitive agreement to acquire Human Genome Sciences Inc. from GSK plc (LSE:GSK) for $280 million.

Spero Therapeutics, Inc. Announces Nda Resubmission of Tebipenem Hbr by Gsk to the Fda for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

GSK plc Announces Exdensur (depemokimab) Approved by US FDA for the Treatment of Severe Asthma

GSK plc Announces the Marketing Authorisation of Exdensur ( Depemokimab) by the UK's Medicines and Healthcare Products Regulatory Agency

GSK plc Announces US FDA Approval Of Blujepa For Gonorrhoea Indication

GSK plc Receives Orphan Drug Designation from US Food and Drug Administration for the Treatment of Small-Cell Lung Cancer

GSK plc Upgrades Earnings Guidance for the Year Ending December 31, 2025

GSK plc Announces US FDA Approves Blenrep (Belantamab Mafodotin-Blmf) in Combination with Bortezomib and Dexamethasone (BVd) for Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma

GSK plc Announces Positive Phase III Data for Next-Generation Low Carbon Version of Ventolin Metered Dose Inhaler

GSK's Shingrix New Prefilled Syringe Presentation Receives Positive CHMP Opinion

GSK's Shingrix Approved in China for Prevention of Shingles in Adults Aged 18 and over Who are at Increased Risk Due to Immunodeficiency or Immunosuppression

GSK plc to Report Q3, 2025 Results on Oct 29, 2025

GSK plc Announces Major Update to Vaccine Track

US Food and Drug Administration Accepts GSK plc's Gepotidacin as an Oral Option for the Treatment of Unplicated Urogenital Grogenital Grogenital Gonorrhoea

GSK plc Provides Update on US Settlement of CureVac/BioNTech mRNA Patent litigation

GSK plc Declares Second Interim Dividend for Second Quarter of 2025, Payable on 9 October 2025

GSK plc Announces Blenrep (Belantamab Mafodotin) Combinations Approved in EU for Treatment of Relapsed/Refractory Multiple Myeloma

GSK plc Provides Update on US FDA Advisory Committee Review of Blenrep (belantamab Mafodotin-blmf) Combinations

US FDA Accepts Application to Review Expanded Use of GSK's RSV Vaccine, Arexvy, for Adults 18-49 At Increased Risk

GSK plc (LSE:GSK) completed the acquisition of Efimosfermin alfa drug from Boston Pharmaceuticals Inc.

GSK plc Announces FDA Approves Benlysta (belimumab) Autoinjector for Children with Active Lupus Nephritis

Gsk plc Announces Japan's Ministry of Health, Labour and Welfare Accepts Regulatory Application to Expand Use of Gsk's Rsv Vaccine

GSK plc Announces the Linked by Lupus: Optimal Care Initiative to Help Support Individuals with Lupus in the US

GSK plc's RSV Vaccine Accepts for Regulatory Review by the European Medicines Agency to Expand Use in Adults 18 Years and Older

GSK plc announces the US Food and Drug Administration has accepted for review the NDA for linerixibat

GSK plc and Spero Therapeutics Announces PIVOT-PO Phase III Study for Tebipenem HBr Starts Early for Efficacy

GSK plc Announces Blenrep (Belantamab Mafodotin) Combination Receive Positive CHMP Opinion in Relapsed/Refractory Multiple Myeloma

GSK plc Announces Approval Ofenrep Combinations by Japan's Ministry of Health, Labour and Welfare for the Treatment of Adults with Relapsed/Refractory Multiple Myeloma

GSK plc (LSE:GSK) agreed to acquire Efimosfermin alfa drug from Boston Pharmaceuticals Inc. for $2 billion.

GSK plc Announces Positive Results for Nucala

GSK plc Announces the Authorisation of Blenrep by the Medicines and Healthcare Products Regulatory Agency

GSK plc Recommends the Use of RSV Vaccines Including GSK'sAREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted)

GSK plc to Report Q1, 2025 Results on Apr 30, 2025

GSK's Omjjara (Momelotinib) Approves in Singapore as the First Treatment Indicated for Myelofibrosis Patients with Anaemia

GSK plc, Annual General Meeting, May 07, 2025

US Food and Drug Administration Accepts Depemokimab Application for the Use of D Epemokimab in Two Indications

GSK plc (LSE:GSK) announces an Equity Buyback for £2,000 million worth of its shares.

GSK plc (LSE:GSK) completed the acquisition of IDRX, Inc. from a group of shareholders.

GSK plc Announces That The Chinanational Medical Products Administration Has Accepted for Review the New Drug Application for the Use of Nucala (Mepolizumab)

GSK plc Announces Board and Committee Changes

Gsk plc Announces Approval of Penmenvy, Gsk’S 5-In-1 Meningococcal Vaccine by US FDA

GSK plc Provides Earnings Guidance for the Full-Year of 2025; Provides Earning Guidance for 2026

Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against GSK plc

GSK plc Announces Acceptancy of Depemokimab Applications for Review in China and Japan for Asthma with Type 2 Inflammation and CRSwNP

Gsk plc Announces the European Medicines Agency Accepts for Review the Regulatory Application of A Prefilled Syringe Presentation of Shingrix

GSK plc Announces the European Commission Approval to Expand the Use of Jemperli Plus Chemotherapy (Caroplatin and Paclitaxel) for First-Line Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Cancer

GSK plc to Report Q4, 2024 Results on Feb 05, 2025

GSK plc (LSE:GSK) entered into an agreement to acquire IDRX, Inc. from a group of shareholders for approximately $1.2 billion.

Us Food and Drug Administration Accepts GSK Plc's Shingrix New Prefilled Syringe Presentation of Shingrix for the Prevention of Shingles (Herpes Zoster)